menu
    • menu
    [{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"GPCR","graph1":"Immunology","graph2":"Undisclosed","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OMass Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"1","companyTruncated":"OMass Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Affyxell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avacta Group \/ Affyxell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ Affyxell Therapeutics"},{"orgOrder":0,"company":"Mogrify","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mogrify","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mogrify \/ Sangamo Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Mogrify \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Camallergy","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"Camallergy","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Camallergy \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Camallergy \/ OnDosis"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Camallergy

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Camallergy

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : OnDosis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment

                            Details : Under the partnership, Camallergy's innovative therapies is combined with OnDosis' cutting-edge Dosage Manager device technology to address the challenges physicians face in offering oral immunotherapy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            November 29, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : OnDosis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tiziana Life Sciences

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Tiziana Life Sciences

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Thinkequity

                            Deal Size : $57.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

                            Details : Tiziana intends to use the net proceeds to advance the clinical development of Foralumab, to initiate a trial in HCC patients with Milciclib, to expedite clinical development of TZLS-501 for coronavirus COVID-19, and for working capital and other general...

                            Product Name : TZLS-401

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 08, 2020

                            Lead Product(s) : Foralumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Thinkequity

                            Deal Size : $57.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mogrify

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Mogrify

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Sangamo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sangamo taps Mogrify for off-the-shelf CAR-Treg project

                            Details : Mogrify will discover and optimize cell conversion technology from iPSCs or ESCs to regulatory T cells. Sangamo will use Mogrify’s technology to create Tregs from iPSCs or ESCs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 21, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Sangamo Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avacta Group

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            Avacta Group

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Stefin A

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Affyxell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Avacta and Daewoong collaborate with AffyXell Therapeutics

                            Details : License agreement to utilise Affimer® proteins in next generation cell and gene therapies.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : Stefin A

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Affyxell Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OMass Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed

                            OMass Therapeutics

                            United Kingdom arrow
                            Discovery Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Syncona Limited

                            Deal Size : $53.6 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            OMass Therapeutics Announces £27.5 M Extended Series A Financing

                            Details : Proceeds from this financing will allow the Company to progress a pipeline of small molecule therapeutics for patients suffering from immunological and genetic disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 17, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Syncona Limited

                            Deal Size : $53.6 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth